Skin Biopsy Market significant CAGR to be Achieved by Worldwide Major Vendors, Recent Trends and Forecast till 2023

Skin Biopsy Market Information: By Type (Shave Biopsy, Excisional Biopsy, Incisional Biopsy), Device (Needle Based Biopsy Guns, Biopsy Forceps, Biopsy Needles), Indication (Cancer, Actinic Keratosis, Skin Infection), End User - Global Forecast till 2023

Market Synopsis

The global skin biopsy market is expected to exhibit a CAGR of 9.4% over the forecast period from 2017 to 2023, according to a new report from Market Research Future (MRFR). The global skin biopsy market is analyzed in detail in the report, which takes a look at the historical growth trajectory of the global skin biopsy market to point out key indicators of the market’s movement. Using these indicators, the report presents a detailed landscape of the skin biopsy market’s potential growth trajectory over the forecast period. The report also compiles an extended analysis on the market’s key drivers as well as the key restraints likely to hold back the market over the forecast period.

Skin biopsy is a procedure involving the removal of skin for examination and providing information about any disease or clinical conditions. It is performed to determine the presence of any cancerous cells or any type of skin diseases. Skin cancer, actinic keratosis, dermatitis, psoriasis, and skin infection are various diseases that can be diagnosed through skin biopsy. During the procedure, the sample taken from the affected or diseased part of the skin is placed in formaldehyde solution, the tissue is processed and then examined under the microscope. 

Rising of skin cancer and number of skin disease such as psoriasis, viral skin infection, and dermatitis, and growing demand for minimally invasive medical procedures are major factors contributing to the market growth. Furthermore, rising expenditure on the medical devices and instruments boost the market growth. However, high cost of treatment for skin diseases restrains the market.

Key Players                            

Some of the key players in this market are Boston Scientific Corporation (U.S.), COOK Medical (U.S.), BD (U.S.), DTR Medical Ltd (U.K), Devicor Medical Products, Inc. part of Leica Biosystems. (U.S.), Gallini Srl (Italy), Hologic, Inc. (U.S.), and Cardinal Health (U.S.).

Segments                                                                                                                                            

The global skin biopsy market is segmented on the basis of type, devices, indication, and end user.

On the basis of indication, the market is segmented into actinic keratosis, dermatitis, psoriasis, skin infection, cancer, and others.

Skin infection is further segmented into viral infections, deep fungal infections, basal cell carcinoma, squamous cell carcinoma, and melanoma.

On the basis of end user, the market is segmented into hospitals, dermatology clinics, and others.

On the basis of type, market is segmented into shave biopsy, punch biopsy, excisional biopsy and incisional biopsy.

On the basis of devices, the market is segmented into needle based biopsy guns, biopsy curettes and punches, guidance systems, biopsy forceps, biopsy needles and others.

Regional Analysis    

America secures a leading position in the market for skin biopsy owing to the rising prevalence of skin diseases and cancer in the U.S. and presence of key market players. According to the American Academy of Dermatology (AAD), skin diseases affects one in every fourth American. The prevalence of skin diseases is also found to be increasing in Canada.

Europe is the second largest market for skin biopsy. Increasing prevalence of skin diseases such as fungal infections, and dermatitis, and increasing demand for technological advanced diagnostic services further drive the market growth.

The Middle East & Africa also show a steady rise in the market owing to increasing prevalence of diabetes and other chronic diseases

The market in Asia Pacific is expected to grow at the fastest pace and is driven by the rising geriatric population, rising prevalence of skin cancer, and increasing number of biopsies performed in the hospitals.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Hypersensitivity Pneumonitis Market: 2019 Global Sales, Size, Share, Competitive Analysis, Upcoming Opportunities, and Forecast To 2023

Hypersensitivity Pneumonitis Market Research Report, By Type (Acute, Subacute, Chronic), By Therapy (Diagnosis (Chest Lung Function Tests, X-Ray, Lung Biopsy) Treatment (Pharmacological (Corticosteroid))), End User (Hospital) - Global Forecast till 2023

Market Synopsis of Global Hypersensitivity Pneumonitis Market

Hypersensitivity pneumonitis is a complex syndrome caused due to exposure to a variety of organic particles. Hypersensitivity pneumonitis is divided into three types, acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis which is based on the based on the duration of the illness. According to the American Academy of Allergy, Asthma & Immunology (2013), 10%-30% of the global population suffers from allergic rhinitis. Increasing prevalence of patients suffering from hypersensitivity pneumonitis, and increasing pollution have boosted the growth of the market. Additionally, According to the American Academy of Allergy, Asthma & Immunology, in 2013, globally, sensitization rates to one or more common allergens among school children is approximately 40%-50% and in 2012, 10.6% children were diagnosed with respiratory allergies. Moreover, increasing prevalence of respiratory diseases, increasing healthcare expenditure, and strong government support for research & development have also contributed to the growth of the market. Rising geriatric population also supports the growth of the market. However, lack of long term treatment and awareness about the diseases may lead to slow the growth of the market.

The global hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users.

On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis.

On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others.

On the basis of end users, the market is segmented into hospital, clinics, and others.

Global Hypersensitivity Pneumonitis Market   - Regional Analysis

America commands the largest market for hypersensitivity pneumonitis majorly due to increasing patient population. According to the Asthma and Allergy Foundation of America, in 2015, nasal allergies affect about 50 million people in the United States of which 30 % are adults and 40 % are children. Additionally, peanut is the most common allergen followed by milk and shellfish. In 2015, 4.2 million children in the US have food allergies. Changing environment condition, and increasing government support have supported the market growth.

On regional basis, the Americas Hypersensitivity pneumonitis market is segmented into two major regions, North America and South America. North America commands the largest market in this region. North America is further segmented into the US and Canada. High healthcare spending, increasing prevalence of the respiratory diseases and government encouragement will boost the market in North America. However, South America shows the fastest growth for the American market owing to the presence of huge opportunities for the development of the market.

The Americas hypersensitivity pneumonitis market is segmented on the basis of types, therapy, and end users. On the basis of types, the market is segmented into acute hypersensitivity pneumonitis, subacute hypersensitivity pneumonitis, and chronic hypersensitivity pneumonitis. On the basis of therapy, the market is segmented into diagnosis, and treatment. Diagnosis is further segmented into chest lung function tests, X-ray, lung biopsy, and others. Treatment is further classified into pharmacological and non-pharmacological. Pharmacological is further segmented into corticosteroid therapy, immunosuppressive therapy and others. On the basis of end users, the market is segmented into hospital, clinics, and others.

Europe is the second largest market for hypersensitivity pneumonitis, which is followed by Asia Pacific. Availability of funds for research, changing environment conditions and government support for research & development will drive the market.

Asia Pacific is expecting fastest growth for the market due to the presence of a huge patient population, presence of huge opportunity in the market, and huge geriatric population. India and China are the major contributors for the market. According to the WHO in 2013, approximately 20-30% of Indian population suffers from at least one allergic disease and 8.7% of the total china’s population suffers from allergic rhinitis. Increasing prevalence of diseases have boosted the growth of the Asia Pacific market.

On the other hand, the Middle East & Africa holds the least share in the global hypersensitivity pneumonitis market due limited development in the healthcare sector and poor economy in Africa region. Majority of the market of this region is held by the Middle East due to huge healthcare spending.

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Cubital Tunnel Syndrome Market 2019 Global Analysis, Opportunities, Trends and Forecast to 2023

Cubital Tunnel Syndrome Market Research Report: By Cause (Injury, Noncancerous Fatty Tumor, Bone Tumor, Inflammation), Treatment (Diagnosis (MRI, X-Ray), Therapy (Non-Operative, Operative)), End User (Hospital, Retail Pharmacy) - Global Forecast Till 2023

Market Scenario

Asia Pacific is the fastest growing region in the global market due to the presence of a increasing patient population, continuously developing economies, and increasing need for the better treatment. According to the WHO report published in 2015, Asia's elderly population is projected to reach nearly 923 million by 2050.

The global cubital tunnel syndrome market is expected to grow at a CAGR of 5.6% during forecast period 2017-2023. 

Cubital tunnel syndrome is a condition of increased pressure on the ulnar nerve in the elbow. The ulnar nerve controls muscles and feeling in the hand. Furthermore, it can be caused by direct pressure, stretching, or decreased blood flow to the ulnar nerve. According to the WHO (2014), the incidence of carpal tunnel syndrome is >3 new cases per 1000 persons every year. Women are 3-4 times more susceptible than men. Increasing prevalence of the cubital tunnel syndrome is the major driving factor for the growth of the market. Moreover, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the market. According to research, geriatric population is more likely to suffer from this disease; According to the Aging World in 2015, 562 million (or 8.0 %) were aged 65 and over across the globe, this has increased the prevalence of the diseases and contributed to the growth of the market. However, lack of awareness among people and high cost of surgeries may restrain the growth of the market.

Segmentation

The global cubital tunnel syndrome market is segmented on the basis of causes, treatment, and end users.

On the basis of causes, the market is segmented into injury, noncancerous fatty tumors, bone tumors, inflammation, and others.

On the basis of treatment, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into nerve compression tests, X-ray, electrodiagnostic studies, MRI, and others. The therapy is further segmented into non-operative, and operative. The non-operative is further classified into NSAIDs and steroids.
On the basis of end users, the market is segmented into hospital, retail pharmacy, and other. 

Regional Analysis

The Americas dominates the global cubital tunnel syndrome market owing to large patient population. Additionally, increasing geriatric population, changing lifestyle, and increasing healthcare expenditure have boosted the growth of the market in America. According to the Population Reference Bureau, the number of Americans ages 65 and over is projected to be more than double from 46 million in 2016 to over 98 million by 2060. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.

Europe is the second largest cubital tunnel syndrome market, which is followed by Asia Pacific. Huge geriatric population, availability of funds for research, and government support for research & development projected to drive the market in Europe.

Whereas, the Middle East & Africa owns the least share of  the global cubital tunnel syndrome market due to the presence of poor economy, especially, in Africa region. The market of this region is dominated by the Middle East due to well-developed healthcare sector and huge healthcare expenditure.

Key Players in Global Cubital Tunnel Syndrome Market

The major key players in the global cubital tunnel syndrome market: Eli Lily and Company (US), GlaxoSmithKline PLC (UK), Pfizer Inc., Depomed Inc., Novartis International AG (Switzerland), Johnson & Johnson Services Inc. (US), Bristol-Myers Squibb and Company (US),  Sanofi S.A. (France), Debiopharm Group (Switzerland), Baxter Healthcare Corporation (US), Biogen Idec Inc. (US), Amneal Pharmaceuticals LLC. (US), Amgen, Inc. (US)

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Global Ear Infection Treatment Market 2019 Size, Status and Forecast to 2023

Ear Infection Treatment Market Information: By Type (Middle Ear, Inner Ear), By Pathogen (Bacteria, Virus) Diagnosis (Hearing Test, Microbial Test, Otoscopy & Tympanometry, Computerized Tomography), Treatment (Drugs), End-User - Global Forecast till 2023

Market Scenario

An ear infection is invasion of the ear tissue by bacteria or virus causing pain, inflammation and fluid build-up in the ear. Most ear infections are acute affecting for a short duration but chronic ear infections can cause permanent damage to the middle and inner ear.

Infants younger than 6 months have higher chances of infection accompanied by a fever higher than 102°F and severe ear pain. According to the healthline, middle ear infections occur in 80 % of children by the time they reach age three. Swimmer’s ear is a common outer ear infection affecting approximately 0.4 million healthcare visits annually in the United States.

The Global Ear Infection Treatment Market is expected to reach USD 22.3 Billion by 2023, and the market is projected to grow at a CAGR of Approx 6.6 % during the forecast period 2017-2023.

The developments in the surgery segment, such as minimal invasive laparoscopy surgery, is driving the global ear infection treatment market. The drug segment is, however, suffering from market fragmentation, which has put pressure on the price margins. The loss of patents and the rise of counterfeited drugs has also restricted the market growth. The other market constrains are high cost of surgery and complications of the surgery. Market development represents the best strategy for the market growth. The market is expected to witness exponential growth over the review period owing to minimal invasive surgical procedures.

Product development represents the best strategy for dominating the market as surgery is the definitive treatment for high ear infection treatment market. The advent of minimally invasive treatment and diagnostic techniques such as computed tomography has changed the market landscape to a large extent. Miniaturization of surgical instruments and development of minimal invasive treatment such as robotic laparoscopy is expected to drive the future market in the developed regions of North America and Europe. Cost of the product will be a decisive factor in the developing regions such as Asia Pacific and especially Africa. The growing demand for better and minimally invasive surgical procedures is the greatest unmet need of the market.

Ear Infection Treatment Industry Segments:

The global ear infection treatment market has been segmented on the basis of type, pathogen diagnosis, treatment, and end user.

Based on the type, the market has been segmented as outer ear, middle ear, inner ear.

Based on the diagnosis, the market has been segmented as hearing test, microbial test, otoscopy and tympanometry, Computerized Tomography (CT), other.

Based on the treatment, the market has been segmented as surgery, drugs, and others.

Based on the pathogen, the market has been segmented as bacteria, virus and others.

Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.

The market drivers for global ear infection treatment market are rise in risk factors, increasing awareness regarding the severity of untreated ear infection, development of healthcare, technological development in diagnostic devices and surgery segment especially the advancements in minimally invasive surgery etc. The market restraints are the complications of surgery, high cost of treatment, emergence of bacterial resistance, etc.

Key Players in the Global Ear Infection Treatment Market:

• American Diagnostic Corporation
• Pfizer plc.
• Heine USA Ltd.
• Welch Allyn
• TorquePharma
• Medtronic
• Intersect ENT, Inc.
• Olympus Corporation
• Grace Medical
• American Diagnostic Corporation.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development.

Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Global Drug Allergy Market Recent Trends, Growth Opportunities, Forecast by Application and Types to 2023

Increasing awareness about various allergies, the introduction of the new treatment of products and rising demand from emerging markets drives the growth of the global market. Drug allergy is one of the most common types of allergies. It is the hyper sensitivity of the immune system to drug or medication. Any types of drugs such as prescription, nonprescription or herbal can induce drug allergy. Some common symptoms of the drug allergies are hives, skin rash, itching of the eyes or skin, swelling of the face, lips, or tongue, wheezing, and others. Treatment can relieve and prevent severe reactions.

New research to prevent drug allergies is another key driver for the market. The global drug allergy market is growing moderately and is expected to continue its growth over the forecast period.

Reaction to drugs and other medication can differ from patient to patient, with drug allergies becoming increasingly common. Market Research Future (MRFR) in its latest report has discovered that the market is due to witness a CAGR of 5.1% during the forecast period of 2017 to 2023. MRFR has further ascertained that the drug allergy market share is expected to grow to reach an estimated value of USD 4,764 Mn by the end of 2023

Top Key Players

AstraZeneca (UK), Bayer (US), Circassia (US), HAL Allergy Group (the Netherlands), Johnson & Johnson Services, Inc. (US), MAGNA Pharmaceuticals, Inc. (US), Stallergenes Greer (UK), and others.

Segments                   

The global drug allergy market is segmented on the basis of type, which comprises of immunologic, nonimmunologic, and others. Immunologic allergy is sub-segmented into type I reaction, type II reaction, type III reaction, type IV reaction, and others. The non-immunologic allergy is sub-segmented into predictable, unpredictable, and others. The predictable allergy is further segmented into pharmacologic side effect, secondary pharmacologic side effect, drug toxicity, drug-drug interactions, drug overdose, and others. The unpredictable segment is further sub-segmented into pseudoallergic, idiosyncratic, intolerance, and others.

On the basis of diagnosis, the market is segmented into skin tests, blood tests, patch test, and others. The skin test is further segmented into prick or scratch test, intradermal test, and others.

On the basis of treatments, the market is segmented into antihistamines, corticosteroids, treatment of anaphylaxis, withdrawal of the drug, and others. Antihistamines are further sub-segmented into azelastine eyedrops, azelastine nasal sprays, carbinoxamine, cyproheptadine, desloratadine, diphenhydramine, emedastine eyedrops, hydroxyzine, levocabastine eyedrops, levocabastine oral, and others. Corticosteroids is further sub-segmented into topical steroids, inhaled steroids, and others. Inhaled steroids is further segmented into flunisolide, fluticasone furoate, fluticasone propionate, triamcinolone acetonide, beclomethasone dipropionate, budesonide, and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Regional Analysis

The Americas dominate the global market for the drug allergy. The Americas mainly include North America and Latin America, out of which North America accounts for the majority of the market share of this region. The US is the top revenue generating market in North America and is one of the important markets for the global drug allergy treatment. Approximately 10% of the total US population have drug allergies. Latin America drug allergy market is also growing significantly and mainly includes Brazil, Argentina, and Chile. Europe is the second largest market in the globe owing to increasing cases of drug allergy.

Europe is mainly divided into Eastern Europe and Western Europe. More developed Western European countries like Germany, UK and France are dominating this market while East European region is also growing significantly. Increasing cases of drug allergies are one of the major factors for the growth of the Europe market.

Asia Pacific region is showing the fastest growth rate in the global drug allergy market due to some major factors such as increasing awareness about various drug allergies, availability of treatment products, and rapidly improving healthcare facilities. Japan is holding the major market share while China’s drug allergy market is expected to show the fastest growth in this region. Changing healthcare practices and increasing patient involvement play an important role in the growth of this market.

The Middle East & Africa is expected to experience a limited growth due to lack of awareness about diseases, traditional healthcare practices, etc. The Middle East region dominates the market due to some of the major factors, for instance, developed healthcare facilities and government support to improve public health.

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Tendinitis Treatment Market, Segments, Growth and Value Chain 2019

Tendinitis treatment market information, by condition (tennis elbow, golfer's elbow, and others), by diagnosis (physical exam, imaging tests, and others), by treatment (medications, therapy, and others), by end user- global forecast till 2023

Market synopsis of Global Tendinitis Treatment market:

Market Scenario:

An expert on premium research reports, Market Research Future predicts that Global tendinitis treatment market is expected to grow at the CAGR of ~3.8% during the forecast period and is estimated to reach USD 426.4 million by 2023. According to a recent study report published by the Market Research Future, the global tendinitis treatment market growth is expected to gain eminence over the forecast period. The market is forecasted to demonstrate a steady growth by 2023, surpassing USD 426.4 million with a constant CAGR during the anticipated period (2017 – 2023).

Tendinitis is the inflammation of the tendon, thick cords that attach the muscles to the bone. The inflammation occurs as a result of sudden injury to the tendon, repetitive movement or disease condition such as diabetes, rheumatoid arthritis, gout, Reiter's syndrome or lupus. In case of patients with gout, the uric acid crystals appear in the tendon sheath leading to friction. Tendinitis is found to be prevalent among athletes and is one of the common sport injuries in sport players, especially tennis, golf and others. Various pharmacological and non-pharmacological treatments are available for the treatment of tendinitis. Non-steroidal anti-inflammatory drugs (NSAIDs) constitute the preliminary treatment options. Other treatments including physical therapy, rest, and occupational therapy. Surgery is the last resort for tendinitis, and is only recommended in case of severe damage to the tendon that cannot be treated using pharmacological treatment options.

Key players for Global Tendinitis Treatment Market:                                   

• Almatica Pharma, Inc. (US),
• AstraZeneca (US),
• Bayer (Germany),
• Boehringer Ingelheim Pharmaceuticals, Inc. (US),
• Merck & Co., Inc (US),
• Pfizer (US).

Intended Audience:

• Tendinitis medicines manufacturers
• Tendinitis medicines and treatment providers
• Medical Research laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Segments:

                                                                                                                                        

Global tendinitis treatment market has been segmented on the basis of condition which comprises of tennis elbow, golfer's elbow, pitcher's shoulder, swimmer's shoulder, jumper's knee, and others.

On the basis of treatments, the market has been segmented into medications, therapy, surgical repair, and others. Medication sub-segmented into pain relievers, corticosteroids, Platelet-Rich Plasma (PRP), and others. Therapy is further sub-segmented into hot and cold therapy, physical therapy, occupational therapy, and others.

On the basis of diagnosis, the market is segmented into physical exam, imaging tests, and others. Imaging test is sub-segmented into ultrasound, Magnetic Resonance Imaging (MRI) scans, and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Regional analysis

Considering the global scenario of the market, America is the top contributor in this market. The Americas mainly includes North America and South America. Due to developed healthcare infrastructure and increasing R&D funding, US is dominating country in this region. Europe is second largest market for tendinitis treatment. Due to innovative product development and rapid adoption of new treatments, Germany is dominating this market. Asia Pacific is witnessing rapid growth in this market which is mainly due to rapidly changing healthcare sector, increasing awareness, and rising healthcare expenditure. Middle East and Africa is expected to have limited growth while Middle Eastern countries are expected to dominate this market during the forecast period.

Competitive Analysis

The market for tendinitis treatment is characterised by the presence of several well-established and small players, the global market of tendinitis treatment appears to be highly competitive and fragmented. Major players are increasingly expanding their footprint in the emerging nations, making it putting pressure on the regional players, especially in terms of features such as type, product portfolios, and pricing. The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The tendinitis treatment market appears to be highly competitive owing to the presence of several large and small key players accounting for a substantial market share. Many leading players are concentrated in the Americas owing to well-established market and high healthcare expenditures; these players have expanded their market in other region as well. Furthermore, the companies such as Abbott, AstraZeneca, Teva, and Pfizer are well-established in European market. The major four players namely Abbott, AstraZeneca, Teva, and Pfizer accounted for more than 17% share of the Americas and Europe tendinitis market.

In April 2017, Pfizer entered into a merger with Allergan to gain access for Allergan's portfolio including Botox, Viagra, the Prevnar pneumonia vaccine, and treatments for ailments including Alzheimer’s and rheumatoid arthritis.

Furthermore, in July 2017, Merck & Co.Inc & AstraZeneca entered into strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types.   

Furthermore, in November 2016, AstraZeneca announced a licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc., for the global rights to MEDI2070.

Moreover, May 2014, the company acquired Merck & Co., Inc.’s non-prescription business to become the OTC leader in North America and Latin America & achieve top global positions in key OTC product categories.

Therefore, the growing key business strategies will help the key competitors to expand their presence in various parts of the globe for their competitive products and will has spurred the growth of the market.  

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Keratoconus Treatment Market, Segments, Growth and Value Chain 2019

Keratoconus treatment market information, by type (Forme Fruste keratoconus, Corneal Hydrops, and others), by diagnosis (Computerized corneal mapping, Keratometry, and others), by treatment (Lenses, Surgery, and others), by end user- global forecast till 2023

Market Scenario:

The Global Keratoconus Treatment Market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.

Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth.

The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%.

Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.

Further about seven percent of those affected have a family history of the condition, proposed environmental factors comprise of rubbing eyes and allergies. The fundamental mechanism involves changes of the cornea to a cone shape. Diagnosis is by examination with a slit lamp.

Moreover initially the condition can typically be corrected with glasses or soft contact lenses. As the disease worsens special contact lenses may be required. In most people the disease stabilizes after a few years without severe vision problems. In a small number of Keratoconus KC is a condition of the eye which results in liberal thinning of the cornea. This may result in blurry vision, double vision, near sightedness, astigmatism, and light sensitivity. Usually both eyes are affected. In more severe cases a scarring or a circle may be seen within the cornea. While the cause is unknown, it is thought to occur due to a combination of genetic, environmental, and hormonal factors.

Key Players for Global Keratoconus Treatment Market:                               

Some of the key players in this market are: Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore), Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), Novartis AG (Switzerland), Optik Seis (Indonesia), and SAFILENS S.R.L. (Italy), and others.

Segmentations:                                                                                                                                        

Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.

On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.

On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.

On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery is sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study is required to implement this treatment option.

Regional

Considering the global scenario of the market, America is the highest revenue generator with North American region contributing the most. North America mainly includes US and Canada. US is one of the dominant markets not only in America but also in the global market. European market is the second largest and UK is believed to be the fastest growing market for keratoconus treatment in this region. Increasing awareness, growing purchasing power, and rapidly improving healthcare sector are driving the growth for Asia Pacific keratoconus market. Asia Pacific is one of the high potential market for keratoconus treatment. Due to slow adoption of new treatments and prosucts, Middle East and Africa is expected to grow at steady pace.

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report